ObjectiveTo explore the efficacy and safety of edaravone injection after intravascular interventional therapy in patients with acute cerebral infarction. MethodsA total of 128 patients with acute cerebral infarction performed with superselective arterial thrombolysis were selected and divided into control group or observation group by random number table method, with 64 cases in each group. The control group was administered lipid-lowering and anti-platelet aggregation intervention after superselective arterial thrombolysis, based on which the observation group was given intravenous edaravone injection. The clinical efficacy and the prevalence of adverse reactions were compared between the two groups, and the National Institutes of Health Stroke Scale(NIHSS) score and the content of serum free radicals were analyzed 14 days after intervention. ResultsAfter 14 days of intervention, the efficacy of the observation group was superior to the control group, and the total clinical effective rate in the observation was higher than that in the control( 98.44% vs. 84.38%) (all P＜0.05); the NIHSS score and the content of serum free radicals including ·O2, ·OH, ·ONOO- and ·ON decreased significantly in both groups, and were significantly lower in the observation than in the control (all P＜0.05). ConclusionThe effect of edaravone injection on acute cerebral infarction after intravascular interventional therapy is prominent, for it can significantly improve the neurological function, reduce the content of serum free radicals, and is of high safety, indicating it is worthy of clinical promotion.

无